EQS-Adhoc: IGEA Pharma N.V.: IGEA announces changes in its board

EQS Group-Ad-hoc: IGEA Pharma N.V. / Key word(s): Miscellaneous 
IGEA announces changes in its board 
 
02-Jun-2020 / 22:50 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 KR 
The issuer is solely responsible for the content of this announcement. 
 
*IGEA announces changes in its board* 
 
Hoofddorp, the Netherlands, 2 June 2020. IGEA Pharma N.V. (SIX: IGPH) today 
announced the nomination of Mr. Lieven Baten for election as non-executive 
director of IGEA at the upcoming general meeting on 3 July 2020. Lieven 
Baten is a partner at Acalis, with which IGEA has previously signed a 
strategic partnership for the distribution of its products. 
 
The CV of Lieven Baten is available at 
https://www.igeapharma.nl/category/information-for-shareholders/ [1] 
together with the convening notice, the agenda, the explanatory notes and 
other documents for the general meeting of 3 July 2020. 
 
*** 
 
*About IGEA* 
IGEA Pharma N.V. focuses on health-tech and med-tech products and devices. 
Health-tech products are exclusively preventative. IGEA commercializes an 
Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit 
to measure non-bound copper in the blood and a natural dietary supplement 
branded 'Alz1 Tab' designed to reduce blood heavy metals content), and 
intends to launch a diabetes type II prevention set in 2020. 
Non-ceruloplasmin bound copper is an expected Alzheimer's and diabetes type 
II associated biomarker. Controlling non-bound copper can contribute to 
reduce the risk of Alzheimer's and diabetes type II. Since 2020, IGEA 
furthermore commercializes a COVID-19 rapid test for the detection of IgM 
and IgG SARC-CoV-2 related antibodies. Med-tech products focuses on selected 
solutions and specialities. IGEA commercializes dry aerosol generators for 
air and inanimate environmental surfaces sanitization and air sterilization 
and purification devices and expects to start commercializing medical bags 
and other polymeric based specialty devices for medical use during 2020. 
 
IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered 
in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl 
 
*Contacts* 
Vincenzo Moccia, CEO, [phone], [e-mail] 
Patrick Pozzorini, CFO, [phone], [e-mail] 
 
*Disclaimer* 
This document constitutes neither an offer to buy nor to subscribe 
securities and neither this document nor any part of it should form the 
basis of any investment decision in IGEA. 
 
The information contained in this press release has been carefully prepared. 
However, IGEA bears and assumes no liability of whatever kind for the 
correctness and completeness of the information provided herein. IGEA does 
not assume an obligation of whatever kind to update or correct information 
contained in this press release whether as a result of new information, 
future events or for other reasons. 
 
This publication may contain specific forward-looking statements and 
assessments or intentions concerning IGEA and its business. Such 
forward-looking statements are subject to known and unknown risks, 
uncertainties and other factors which may result in a substantial divergence 
between the actual results, financial situation, development or performance 
of IGEA and those explicitly or implicitly presumed in these statements. 
Against the background of these uncertainties, readers should not rely on 
forward-looking statements. IGEA assumes no responsibility to update 
forward-looking statements or to adapt them to future events or 
developments, except as may be required by law. 
 
Additional features: 
 
File: 20200602 igea nv_press release [2] 
End of ad hoc announcement 
Language:    English 
Company:     IGEA Pharma N.V. 
             Siriusdreef 17 
             2123 WT Hoofddorp 
             Netherlands 
Phone:       [phone] 
E-mail:      [e-mail] 
Internet:    www.igeapharma.nl 
ISIN:        NL0012768675 
Listed:      SIX Swiss Exchange 
EQS News ID: 1061383 
 
End of Announcement EQS Group News Service 
 
1061383 02-Jun-2020 CET/CEST 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=2333bfec6aa5792114657e4e0a2a1fb3&application_id=1061383&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f66be891910bcbee0068a2f4b1985955&application_id=1061383&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

June 02, 2020 16:50 ET (20:50 GMT)